Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
PubMed
28104790
DOI
10.1093/eurheartj/ehw564
PII: ehw564
Knihovny.cz E-zdroje
- Klíčová slova
- Ablation, Atrial fibrillation, Complications, Management, Outcomes, Prospective registry,
- MeSH
- antikoagulancia terapeutické užití MeSH
- délka pobytu statistika a číselné údaje MeSH
- fibrilace síní chirurgie MeSH
- hospitalizace statistika a číselné údaje MeSH
- katetrizační ablace škodlivé účinky metody statistika a číselné údaje MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- pooperační komplikace etiologie MeSH
- předoperační péče MeSH
- prospektivní studie MeSH
- registrace MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- antikoagulancia MeSH
AIMS: The ESC-EHRA Atrial Fibrillation Ablation Long-Term registry is a prospective, multinational study that aims at providing an accurate picture of contemporary real-world ablation for atrial fibrillation (AFib) and its outcome. METHODS AND RESULTS: A total of 104 centres in 27 European countries participated and were asked to enrol 20-50 consecutive patients scheduled for first and re-do AFib ablation. Pre-procedural, procedural and 1-year follow-up data were captured on a web-based electronic case record form. Overall, 3630 patients were included, of which 3593 underwent an AFib ablation (98.9%). Median age was 59 years and 32.4% patients had lone atrial fibrillation. Pulmonary vein isolation was attempted in 98.8% of patients and achieved in 95-97%. AFib-related symptoms were present in 97%. In-hospital complications occurred in 7.8% and one patient died due to an atrioesophageal fistula. One-year follow-up was performed in 3180 (88.6%) at a median of 12.4 months (11.9-13.4) after ablation: 52.8% by clinical visit, 44.2% by telephone contact and 3.0% by contact with the general practitioner. At 12-months, the success rate with or without antiarrhythmic drugs (AADs) was 73.6%. A significant portion (46%) was still on AADs. Late complications included 14 additional deaths (4 cardiac, 4 vascular, 6 other causes) and 333 (10.7%) other complications. CONCLUSION: AFib ablation in clinical practice is mostly performed in symptomatic, relatively young and otherwise healthy patients. Overall success rate is satisfactory, but complication rate remains considerable and a significant portion of patients remain on AADs. Monitoring after ablation shows wide variations. Antithrombotic treatment after ablation shows insufficient guideline-adherence.
Arrhythmia Unit Cardiology Department University Hospital Virgen de la Victoria Malaga
Associazione Nazionale Medici Cardiologi Ospedalieri Research Center Florence Italy
Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic
Department of Cardiology Institution of Medical Science Uppsala University Uppsala Sweden
Department of Electrophysiology University Leipzig Heart Center Leipzig Germany
EURObservational Research Programme European Society of Cardiology Sophia Antipolis France
GVM Care and Research E S Health Science Foundation Maria Cecilia Hospital Cotignola Italy
Citace poskytuje Crossref.org
Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation